Pentosan polysulfate

For interstitial cystitis: FDA-approved oral dose is 100 mg three times daily (300 mg/day). For osteoarthritis: injectable formulations have been studied (dosing varies). Note: long-term oral use (>15 years at standard doses) carries a small risk of pigmentary maculopathy (vision changes); low-dose injectable PPS does not appear to carry this risk. Regular eye exams recommended with prolonged use.

Replaces or repairs the damaged glycosaminoglycan coating of the bladder urothelium, reducing permeability and protecting underlying tissue from irritants in urine.

Inhibits cartilage-degrading enzymes including metalloproteinases (MMP-3) and reduces inflammatory mediators (IL-1, TNF-alpha), retarding degradation of articular cartilage in osteoarthritis.

Stimulates synthesis of hyaluronic acid, the major non-proteinaceous component of synovial fluid, improving joint lubrication and function.

Binds fibroblast growth factors (FGFs) and other heparin-binding growth factors. Exhibits mild anticoagulant and fibrinolytic properties.

FDA-approved oral treatment for interstitial cystitis. Relieves bladder pain and discomfort by restoring the protective bladder lining. Symptom relief typically begins after 3-4 weeks of use.

Acts as a disease-modifying osteoarthritis drug (DMOAD). In clinical studies, over 90% of patients showed decreased pain and functional improvement over 8 weeks, with 80% reporting sustained improvement for one year.

Decreases inflammation through at least 10 different mechanisms, affecting sensory nerve cells, immune cells, chondrocytes, and capillary endothelial cells.

Improves synovial fluid quality through hyaluronic acid stimulation, benefiting joint lubrication and reducing pain with movement including walking and stair climbing.

Effects of pentosan polysulfate sodium on joint structure and function out to six months in naturally-occurring canine osteoarthritis.

PloS one · Stapledon CJM, Krishnan R, Peat RA

Pentosan Polysulfate and Heparin Exhibit Comparable Interactions with Platelet Factor 4, Suggesting a Potential Risk of Thrombocytopenia.

ACS omega · Nizzolo S, Zanzoni S, Holthoff HP

Effects of pentosan polysulfate sodium on synovial fluid biomarkers in moderate to severe knee osteoarthritis: an exploratory, phase 2, randomized, do...

Arthritis research & therapy · Skerrett DL, Stapledon CJM, Ahuja M

Post-marketing safety of pentosan polysulfate sodium: a 21-year pharmacovigilance analysis of the FAERS database.

Frontiers in medicine · Wang B, Xia L, Bao EH

Progression of Presumed Pentosan Polysulfate Sodium Maculopathy After Drug Cessation.

JAMA ophthalmology · Botros E, Kim HS, Stepien KE